Format

Send to

Choose Destination
BMJ Open. 2017 Jun 8;7(6):e016505. doi: 10.1136/bmjopen-2017-016505.

Cohort profile: the Nordic Antireflux Surgery Cohort (NordASCo).

Author information

1
Upper Gastrointestinal Surgery, Department of Molecular Medicine and Surgery, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
2
Impact Assessment Unit, Department of Health Protection, National Institute for Health and Welfare, Tampere, Finland.
3
Centre for Translational Microbiome Research CTMR, Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
4
Science For Life Laboratory (SciLifeLab), Karolinska Institutet, Stockholm, Sweden.
5
Clinic of Gastroenterology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
6
Department of Public Health, University of Copenhagen, Copenhagen, Denmark.
7
Institute for Statistical and Epidemiological Cancer Research, Finnish Cancer Registry, Helsinki, Finland.
8
School of Health Sciences, University of Tampere, Tampere, Finland.
9
Department of Public Health and General Practice, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway.
10
Icelandic Cancer Registry, Icelandic Cancer Society, Reykjavik, Iceland.
11
Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
12
Division of Cancer Studies, King's College London, London, UK.

Abstract

PURPOSE:

To describe a newly created all-Nordic cohort of patients with gastro-oesophageal reflux disease (GORD), entitled the Nordic Antireflux Surgery Cohort (NordASCo), which will be used to compare participants having undergone antireflux surgery with those who have not regarding risk of cancers, other diseases and mortality.

PARTICIPANTS:

Included were individuals with a GORD diagnosis recorded in any of the nationwide patient registries in the Nordic countries (Denmark, Finland, Iceland, Norway and Sweden) in 1964-2014 (with various start and end years in different countries). Data regarding cancer, other diseases and mortality were retrieved from the nationwide registries for cancer, patients and causes of death, respectively.

FINDINGS TO DATE:

The NordASCo includes 945 153 individuals with a diagnosis of GORD. Of these, 48 433 (5.1%) have undergone primary antireflux surgery. Median age at primary antireflux surgery ranged from 47 to 52 years in the different countries. The coding practices of GORD seem to have differed between the Nordic countries.

FUTURE PLANS:

The NordASCo will initially be used to analyse the risk of developing known or potential GORD-related cancers, that is, tumours of the oesophagus, stomach, larynx, pharynx and lung, and to evaluate the mortality in the short-term and long-term perspectives. Additionally, the cohort will be used to evaluate the risk of non-malignant respiratory conditions that might be caused by aspiration of gastric contents.

KEYWORDS:

fundoplication; gastro-oesophageal reflux disease; laparoscopic surgery.; oesophagus

PMID:
28600380
PMCID:
PMC5726097
DOI:
10.1136/bmjopen-2017-016505
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center